Laurus Labs Q2 Results Review. | Techno Glob

BQ Prime’s special research section is based on India’s leading brokers; Combines quality and in-depth equity and business research reports from asset managers and research agencies. These reports provide subscribers of BQ Prime with companies, It provides an opportunity to expand understanding of sectors and the economy.

Laurus Labs Ltd. ’s custom integration business grew 365% YoY; Reported strong growth of 25% QoQ to Rs 720 crore; Due to increased demand from new and existing customers.

Revenue from finished dosage forms fell 70 percent to Rs 149 crore, mainly dragged down by lower antiviral business. The main contributing factors are low volume and low prices.

Generic active pharmaceutical ingredients saw 29% YoY growth on the back of strong growth in other APIs, which increased 93.5% YoY to Rs 224 crore, while continuous ARV APIs recovered 21% YoY to Rs 408 crore.

Laurus Bio reported a soft quarter, up 3.8% at Rs 27 crore.

Click on the attachment to read the full report:


This report was written by a third party. BQ Prime does not guarantee the accuracy of its contents and is not responsible for them in any way. The content in this section does not constitute investment advice. For this, you should always consult a professional based on your individual needs. The views expressed in the report are those of the author’s organization and do not necessarily represent the views of BQ Prime.

Users copy content without the permission of the original owner; No license to modify or distribute.

Source link